Radiation Therapy Shows Promise in Treating Benign Proliferative Diseases of the Extremities

Radiation therapy (RT) has emerged as a promising noninvasive treatment for Dupuytren's disease (DD) and plantar fibromatosis (PF), according to findings from a recent European multicenter trial. These proliferative conditions form painful nodules on the palms and soles, and RT may slow their progression, thereby preserving patient quality of life.

DD affects approximately 3-5% of the U.S. population, whereas PF is less common, with fewer than 200,000 cases nationwide. Both conditions lead to nodules that may develop into contractures, limiting hand and foot function. Despite promising outcomes with RT, awareness within the medical community remains limited.

Dr. Rahul Tendulkar, a staff physician at the Cleveland Clinic Cancer Institute, emphasizes that RT can prevent advancement into more debilitating forms. He notes that primary care providers rarely encounter these treatments, as patients typically see specialists like hand surgeons or podiatrists for different manifestations of the diseases. This compartmentalized care often overlooks comprehensive management strategies that include RT.

Traditionally, surgical intervention was the primary treatment once nodules advanced to contracture. However, this invasive approach often required substantial recovery time, with frequent recurrence. Alternative treatments such as collagenase injections or needle aponeurotomy share similar limitations, which have spurred interest in early-stage intervention with RT.

The European study demonstrated that over two-thirds of patients with symptomatic PF experienced significant relief in pain and improved mobility with RT. At the Cleveland Clinic, patients with either DD or PF have been receiving RT to enhance symptom control and address underlying disease processes. While RT is unlikely to completely eradicate nodules, early application can significantly delay the progression into symptomatic stages.

Dr. Tendulkar advises that the optimal timing for RT is before the onset of significant contracture. Treating DD before a 10-degree contraction is considered ideal, as more severe contractures are unlikely to improve with RT.

In terms of safety, RT offers a low risk of secondary malignancies given the rarity of naturally occurring cancers in the hands or feet. The treatment regimen typically consists of a split course: five consecutive daily doses, a two-month hiatus, followed by another five days of treatment.

Overall, RT provides a valuable, safe alternative for managing DD and PF, potentially deferring more invasive procedures while being effective in the early stages of the conditions.